Gene · 2621
NIH grants2,018
NIH grants whose papers are about the gene, through NIH's grant-paper links.
821 to 840 of 2,018
Download this page as JSON| Grant | Title | GAS6 papers | Newest fiscal year |
|---|---|---|---|
| R01GM127408 | Function and RNA-mediated regulation of SCMH1 in Polycomb repression | 1 | 2021 |
| R01HD088549 | VEGF signaling in placental development and disease | 1 | 2021 |
| R01HL140570 | Impact of the obesity-risk CREBRF p.Arg457Gln variant on energy expenditure, intake, and substrate utilization in Samoans | 1 | 2021 |
| R01HL141570 | Perfusable 3D human cardiac constructs for heart regeneration | 1 | 2021 |
| R01MH112391 | Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era | 1 | 2021 |
| R01MH113858 | Ex vivo signature of psychosis and treatment response in patient-derived neurons | 1 | 2021 |
| R01NS103434 | Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434) | 1 | 2021 |
| R01NS104015 | Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation | 1 | 2021 |
| R01NS105473 | Mitochondrial Fragmentation and Neurodegeneration in Huntington's Disease | 1 | 2021 |
| R03HL154284 | Identifying Contributions of Pulmonary Inflammation to Sleep-Disordered Breathing | 1 | 2021 |
| R21AI144215 | CD40 regulation of acute virus infection | 1 | 2021 |
| R21CA237939 | Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and Venetoclax | 1 | 2021 |
| R21DA049227 | DAT-Psychostimulant mediated dopamine release increases macrophage IL-1beta production through NF-kB activation and inflammasome priming | 1 | 2021 |
| R21ES030334 | Alternative splicing in arsenical skin carcinogenesis | 1 | 2021 |
| R35CA197718 | Dynamic Complexity of Brain Tumor Stem Cells (R35CA197718) | 1 | 2021 |
| R35CA197734 | Targeted Therapy for Leukemia | 1 | 2021 |
| R50CA211479 | Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center | 1 | 2021 |
| RF1AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 1 | 2021 |
| RF1AG074007 | Sex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's Disease | 1 | 2021 |
| S10OD030286 | Orbitrap Exploris 480 Basic System | 1 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2621/grants?page=42